Beta-cell dysfunction, which plays a crucial role in the onset of diabetes, has led to continuous efforts in developing new beta cells. This session introduces mitoribosome insufficiency as a novel mechanism for beta-cell failure and provides innovative insights into beta-cell regeneration through stem cell differentiation and immune evasion methods. Although there are challenges to overcome before clinical application, the session offers a platform to explore pioneering strategies for beta-cell regeneration.

In order to mitigate the risk of cardiometabolic diseases, it is crucial to effectively manage risk factors. This session will delve into the most recent perspective on treatment goals for major cardiovascular risk factors. Prof. Sang-Hyun Kim and Prof. Hae-Young Lee, both from Seoul National University, will explore the targets for low-density lipoprotein -cholesterol and blood pressure, respectively. Prof. Eun-Jung Rhee from Sungkyunkwan University will discuss the target for body weight control.

As the treatment of diabetes improves, effective responses to previously overlooked complications, such as heart failure, sarcopenia, and cognitive dysfunction, have become significant clinical challenges. This session aims to address these crucial issues in depth. Top nationally recognized researchers in the field will present thoughtful summaries of the pathophysiology of emerging diabetic complications and critical points of the latest treatment strategies.

The treatment options for type 2 diabetes are becoming diverse, and there are also a variety of factors to consider when treating the disease. Among the various combinations of drugs, there are combinations that are particularly of advantage due to their strong glucose-lowering effect, beta-cell preservation, weight reduction, or the cardiorenal protective effect. In this session, three renowned speakers will present the advantages of each drug combination. Prof. Jae Hyun Bae will speak on the combination of sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, Prof. Arihiro Kiyosue will cover the combination of GLP-1 receptor agonists and SGLT2 inhibitors, and finally, Prof. Changhee Jung will give a lecture on the advantages of dual injection therapy, GLP-1 receptor agonist and insulin.